CARLSBAD, Calif., June 1, 2012 /PRNewswire/ --Life Technologies Corporation (LIFE) will exhibit platforms for companion diagnostic development and products ideal for basic, translational and clinical cancer research during the American Society for Clinical Oncology (ASCO) Annual Meeting 2012, taking place June 1 June 5, in Chicago, Illinois. In addition, several of the company's customers will present clinical research findings obtained with Life's sequencing technologies.

"Life Technologies offers platforms across the spectrum of genomics and proteomics that can be utilized in companion diagnostic development," said Ronnie Andrews, president of medical sciences at Life Technologies. "We share with our pharma partners a dedication to the movement toward personalized treatments based on the specific defects driving cancer in each individual patient."

In October 2011, Life announced a partnership with GlaxoSmithKline to develop a companion molecular test for a GSK candidate cancer immunotherapy.

Presentations:

AmpliSeq panels accurately identify more than 700 mutations in patient samples Marilyn Li, Ph.D., professor of molecular and human genetics and director of the Cancer Genetics Lab at Baylor College of Medicine, will present a poster demonstrating use of the Life Technologies Ion AmpliSeq cancer panels to sequence 12 archived tumor research samples including FFPE, bone marrow and cell line samples. The authors report that the panel accurately identified all known mutations previously detected using Pyrosequencing or Sanger sequencing and was sensitive enough to detect mutations at frequencies as low as 5% with 99% confidence. The poster will be presented June 4, Monday afternoon from 1:15 to 5:15.

AmpliSeq panels validated in CLIA lab with rapid turn-around for tumor sample sequencing Christopher Corless, M.D., Ph.D., chief medical officer of the Knight Diagnostic Laboratories at Oregon Health & Science University's Knight Cancer Institute, will present results using the Ion Torrent (Life Technologies) AmpliSeq Cancer Panel in a CLIA-licensed/CAP-certified setting. Forty-five FFPE tumor samples were sequenced, and the results matched those obtained via previous mass spec-based genotyping and revealed an additional 27 new mutations. Preliminary data from a custom AmpliSeq GI Stromal Tumor (GIST) panel will also be shown. The poster will be presented June 4, Monday afternoon from 1:15 to 5:15.

Featured Products:

Life Technologies offers cancer researchers the ability to detect mutations in cancer-associated genes using both PCR and sequencing platforms.

Ion Personal Genome Machine (Ion PGM) and Ion Proton Between the benchtop Ion PGMSequencer and the benchtop Ion ProtonSequencer, the Ion Torrent technology can cover any application. The Ion PGMSequencer is ideal for sequencing genes, small genomes, panels of genes, or performing gene expression profiling, and its speed, simplicity and scalability also make it an ideal platform to extend into diagnostics.

The Ion ProtonSequencer is ideal for sequencing both exomes regions in the DNA that code for protein and human genomes. The Ion ProtonI Chip, ideal for sequencing exomes, will be available mid-2012. The Ion ProtonII Chip, ideal for sequencing whole human genomes, will be available six months later. In addition, the Ion ProtonOneTouchsystem automates template prep and a stand-alone Ion ProtonTorrent Server performs the primary and secondary data analysis.

See the original post:
Life Technologies Showcases Leading Technologies for Companion Diagnostic Development, Cancer Research at the ASCO ...